Dyne Therapeutics (NASDAQ:DYN) stock rating lowered by Oppenheimer. October 28, 2026 Key points. * Oppenheimer downgraded Dyne Therapeutics from "outperform" to "market perform" and set a $15 price target, implying 11.45% downside from the prior close. JPMorgan also lowered its rating to "underweight" and cut its target to $10, although the broader analyst consensus remains "Moderate Buy" with a $31.29 average target. * Dyne shares opened at $16.94 after reportedly rising 7.8%; the company has a $3.16 billion market capitalization and trades near the lower end of its 52-week range. Its latest quarterly loss of $1.08 per share missed the $0.75 consensus estimate. * Insiders sold substantial shares: company insiders sold 2.6 million shares worth approximately $65.4 million over the past 90 days, while institutional investors own 96.68% of the stock. Dyne is a clinical-stage biotechnology company developing genetic medicines for muscle diseases, including investigational treatments DYNE-101 and DYNE-251. * Tracking Dyne Therapeutics through earnings season? MarketBeat All Access sends real-time alerts on ratings, earnings, and news - $149 a year, locked in for as long as you stay. Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was downgraded by stock analysts at Oppenheimer from an "outperform" rating to a "market perform" rating in a note issued to investors on Wednesday, MarketBeat.com reports. They currently have a $15.00 price target on the stock. Oppenheimer's price target points to a potential downside of 11.45% from the stock's previous close. Several other equities analysts also recently weighed in on DYN. JPMorgan Chase & Co. downgraded Dyne Therapeutics from a "neutral" rating to an "underweight" rating and dropped their price target for the stock from $17.00 to $10.00 in a research report on Wednesday, September 9th. Wall Street Zen lowered Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Cantor Fitzgerald reiterated a "buy" rating on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Raymond James Financial reissued a "strong-buy" rating and set a $37.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 8th. Finally, Stifel Nicolaus set a $37.00 target price on Dyne Therapeutics in a research report on Wednesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.29. Dyne Therapeutics stock up 7.8%. Shares of DYN stock opened at $16.94 on Wednesday. The stock's 50-day moving average price is $19.09 and its 200 day moving average price is $19.32. Dyne Therapeutics has a 52-week low of $14.00 and a 52-week high of $27.31. The stock has a market capitalization of $3.16 billion, a PE ratio of -5.09 and a beta of 1.12. Discover more MarketBeat All Access MarketBeat Research Tools Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). Analysts expect that Dyne Therapeutics will post -3.59 earnings per share for the current fiscal year. Insider buying and selling. In other Dyne Therapeutics news, CEO John Cox sold 5,658 shares of the firm's stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the sale, the chief executive officer owned 357,507 shares in the company, valued at approximately $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Douglas Kerr sold 3,745 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $24.35, for a total value of $91,190.75. Following the completion of the transaction, the insider directly owned 163,854 shares of the company's stock, valued at $3,989,844.90. This trade represents a 2.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 2,598,706 shares of company stock valued at $65,432,671 in the last 90 days. Corporate insiders own 9.46% of the company's stock. Institutional inflows and outflows. Several institutional investors and hedge funds have recently made changes to their positions in DYN. GAMMA Investing LLC boosted its stake in Dyne Therapeutics by 63.2% during the 3rd quarter. GAMMA Investing LLC now owns 1,882 shares of the company's stock valued at $30,000 after purchasing an additional 729 shares in the last quarter. Sterling Capital Management LLC increased its holdings in shares of Dyne Therapeutics by 89.8% in the third quarter. Sterling Capital Management LLC now owns 3,720 shares of the company's stock valued at $60,000 after buying an additional 1,760 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of Dyne Therapeutics by 56.5% in the 3rd quarter. IFP Advisors Inc now owns 5,879 shares of the company's stock worth $95,000 after acquiring an additional 2,123 shares during the last quarter. Allworth Financial LP acquired a new stake in shares of Dyne Therapeutics during the second quarter worth $62,000. Finally, Wellington Management Group LLP boosted its position in shares of Dyne Therapeutics by 7.3% in the 2nd quarter. Wellington Management Group LLP now owns 52,427 shares of the company's stock valued at $1,164,000 after purchasing an additional 3,545 shares during the period. 96.68% of the stock is currently owned by institutional investors. About Dyne Therapeutics. Dyne Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company's research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge. Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue. Dyne's pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Dyne Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list. While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Continue following MarketBeat

2026 Patient Innovators Awards winners announced at Courier Health's annual Summit. Oct 13, 2026, 09:00 ET Honorees celebrated as biopharma gathered in New York City to chart the future of the patient experience NEW YORK, Oct. 13, 2026 /PRNewswire/ - Courier Health, the leading technology company for managing patient experiences, today announced the winners of the second annual Patient Innovators Awards, which recognize the biopharma teams and leaders going above and beyond to improve patient access, innovation, and overall outcomes. Winners were announced live on October 6th at the third annual Patient Innovators Summit in New York City. The invite-only event brought together Patient Services, Access & Reimbursement, and Commercial IT & Analytics leaders from more than 75 biopharma companies. Together, attendees represented more than 100 disease states and roughly 35 million patients with previously unmet needs. Four teams and one individual were recognized for driving innovation and measurably improving the patient experience: * Rare Disease Champions of the Year: KalVista, a Company of Chiesi Group * Patient Services Team of the Year: Priovant Therapeutics * Field Access Team of the Year: UCB, Inc. * Patient Champion of the Year: Rob Chuba, Alkermes * Patient Innovators of the Year: Bristol Myers Squibb's CAR T-cell therapy Patient Access Support Services (PASS) team "Being named Patient Services Team of the Year is a testament to the team and program we're building," said Lee Liberator, Vice President of Patient Services and Reimbursement at Priovant Therapeutics. "We've built a unique program centered around what patients actually need from us, and we're proud to be recognized for our commitment to innovating and championing a better patient experience." In his opening keynote, Danny Sigurdson, Founder and CEO of Courier Health, described the moment as a fork in the road. As manufacturers take greater internal control of their programs, data ownership, outcomes-based measurement, and AI-enabled workflow innovation have become critical. Organizations that invest in the right foundation will gain greater operational leverage to focus on their core competency - supporting patients and providers - while those that don't will fall further behind. "This year's Patient Innovators Awards winners are proof that a better path, and a brighter future, is already being built," said Danny Sigurdson. "These teams and our individual Patient Champion of the Year aren't afraid to challenge the status quo and rethink how their programs run. They never lose sight of the patient, and it's an honor to recognize their contributions." This year's Patient Innovators Summit featured 11 industry speakers from companies including Alkermes, Beren Therapeutics, Corcept Therapeutics, Compass Pathways, Dyne Therapeutics, Genentech, and Tarus Pharmaceuticals. The audience also heard a powerful firsthand story from Mark Dant, rare disease advocate and Volunteer Executive Director for the Ryan Foundation. About Courier Health Courier Health is a New York City-based technology company on a mission to improve the patient experience for hundreds of millions of people living with a chronic condition or rare disease. The company develops and delivers the fastest-growing patient experience solution for the life sciences industry. Companies that choose Courier Health are achieving double-digit improvements to patient starts, time-to-start and ongoing adherence to life-altering therapies. As host of the invite-only Patient Innovators Summit and publisher of The State of Patient-Centricity in Biopharma report, Courier Health is backed by leading investors, including Oak HC/FT, Norwest and Work-Bench. Follow Courier Health on LinkedIn and learn more at www.courierhealth.com. SOURCE Courier Health

Oil, inflation and trade tensions rattle equities as memory chips hold the line. Global equities fell on oil, inflation and trade risk, while a Korea-led memory-chip rally offset losses in EM and rotated tech away from Nvidia. Monday, 09/14/2026 | The Chart of the week. MSCI World and the US 10-year bond yield both continue to trend higher What happened last week? Global markets Global equities retreated during the week ending on 11 September 2026, with the MSCI ACWI down 1.0% as a cluster of inflation and geopolitical shocks outweighed a still-resilient AI capex narrative. The week opened against a backdrop of a stronger-than-expected August US payrolls report released on the prior Friday close that anchors this period, which had already begun to temper hopes for near-term Federal Reserve easing. From there, sentiment deteriorated further as Brent crude pushed toward $100 a barrel on renewed Middle East hostilities, including reported strikes on Saudi energy infrastructure, at the same time as a US-Canada trade dispute escalated into retaliatory tariffs on both sides of the border. The combination revived the inflation scare that has periodically unsettled markets this year, and it showed up directly in the data: a hotter-than-expected August producer price report on Thursday and an August CPI print on Friday that came in mostly in line at the headline level but hotter on core, alongside a soft reading on consumer sentiment and rising inflation expectations. Both value and growth indices fell in tandem (MSCI ACWI Value and Growth both down roughly 1%), underlining that this was a broad risk-off move rather than a rotation between styles. But emerging markets performed notably better. Nearly every major developed market fell, while MSCI EM rose 1.1%, helped by a powerful rally in Korean equities tied to memory-chip demand. Within Europe specifically, the STOXX Europe 600 pulled back -1.6%, as European equities absorbed both the oil shock and a hold from the ECB. Sector performance reflected this cross-current: energy was one of the few pockets of strength globally as oil rallied, while sectors sensitive to real rates and growth expectations - healthcare, materials, consumer discretionary and construction - underperformed. Within technology, the picture was split: semiconductor names broadly rallied on continued AI infrastructure demand and a rotation toward memory suppliers, even as some of the largest AI beneficiaries of the past two years lagged. The S&P 500 fell 1.1% and the Nasdaq 100 fell 0.4% during the week. The more domestically oriented Russell 2000 index fell 2.1%, underperforming alongside the Dow (-2.1%). Breadth was notably weak - the equal-weighted S&P 500 fell 2.4%, nearly double the headline index's decline, pointing to concentration in the handful of names still holding the market up. Healthcare was the worst-performing sector by a wide margin, down 4.5%. The trigger was Novartis' two consecutive drug trial failures, which drove heavy selling in US-listed peers with competing or adjacent pipelines, including Amgen, Sarepta and Dyne Therapeutics, compounded by company-specific setbacks at Stryker and Boston Scientific. Financials, materials and consumer discretionary also lagged, while technology and energy were the only sectors to post gains. Within technology, the divergence was stark. Semiconductors rallied hard (+5.0%), led by AMD and Intel, as investors rotated toward chipmakers seen as direct beneficiaries of the memory supercycle rather than pure GPU exposure; Dell also surged to a record high on a bullish broker initiation. Nvidia bucked the group, falling 4.3% amid a shift in investor attention toward memory suppliers. Oracle reported strong quarterly results but sold off regardless, as investors focused on the rising capital intensity of its cloud build-out rather than the beat itself. Meta was the standout Magnificent Seven performer, up 6.1% helped by the successful launch of Muse - a standalone personal AI agent. Markets ended the period on a firmer note Friday, snapping a multi-day losing streak, but remained cautious heading into next week's FOMC meeting. European equities declined, with the STOXX Europe 600 down 1.6% in local-currency terms. The DAX (-1.8%) and CAC 40 (-1.2%) both fell, while the FTSE MIB was a rare bright spot, up 0.7%. The most significant single-name driver of the week was Novartis' two consecutive trial failures, which resulted in sharp share-price weakness through the first half of the week; given the stock's weight in Swiss benchmarks, this drove an outsized decline in the Swiss market that stood out even against a weak regional backdrop. At the sector level, energy was the clear outperformer (+2.6%) as oil prices climbed on Middle East supply concerns, while construction and materials, and consumer discretionary, were the weakest performers, reflecting both the drag from higher input costs and broader growth concerns. The ECB's decision to hold rates steady at its Thursday meeting - despite headline inflation running comfortably above target - added a layer of policy uncertainty, with banks ending the period roughly flat as investors weighed the implications for net interest margins against a less hawkish near-term path than some had priced in. Rest of the world Emerging markets were the standout region, with MSCI EM up 1.1% even as developed markets broadly declined. This divergence was driven overwhelmingly by Korea. MSCI Korea surged 6.8% as memory-chip exporters extended their 2026 rally, with South Korean semiconductor shipment data showing another sharp year-on-year increase and reinforcing the narrative of a structural memory supercycle tied to AI infrastructure demand; this also fed the broader rotation within global tech away from GPU-centric names and toward memory suppliers. Taiwan's TAIEX held up relatively well (-0.9%) given its own semiconductor exposure, while China equities slipped modestly (MSCI China -1.6%) amid a comparatively quiet newsflow week for the mainland. India underperformed (-2.8%), while Brazil posted a small gain (+0.4%) and Japan was roughly flat (-0.2%), leaving the region's performance almost entirely a function of the Korean chip story rather than a broad-based emerging-market rally. Its view on equity. Equity asset class Syz Group maintain a neutral equity exposure, balancing a constructive earnings outlook against the headwind from higher real rates. The outlook remains constructive, supported by AI-related investment, broadening earnings participation across sectors and regions, near-record margins and resilient management confidence. Valuations remain supported by earnings growth, with forward estimates rising faster than share prices. The S&P 500 trades close to 20x forward earnings, while Europe, Japan and Asia remain closer to historical averages. The main risk remains a further rise in real yields, increasing discount-rate pressure, although the Treasury's expanded long-dated buybacks provide some support at the long end. 07/09/2026 31/08/2026 03/08/2026 Straight from the desk. Syz the moment. Sign-up out loud. Please note that you can unsubscribe at any time by clicking on the link in the footer of its newsletters. Thinking out loud. Investing with intelligence. Its latest research, commentary and market outlooks